GRM5 and fragile X syndrome: In 15 of the studies showing phenotype reversal with mGluR5 NAMs in FXS mouse models, including the studies using AFQ056, investigators were blinded to treatment groups and/or assessment of outcomes (Supplemental Table 1) and used littermates as controls chosen without obvious bias; 2 studies even used a true randomization scheme.